Product Images Lurasidone Hydrochloride

This is a description of a medication - Lurasidone Hydrochloride Tablets 20 mg. Each tablet contains 20 mg of Lurasidone HCI. The dosage and use information can be found in the package insert. It is recommended to store the medication at a temperature between 20 to 25°C. The medication packaging specifies that only 30 tablets are included. For more information, you can contact USS at 1-866-495-1995. The medication is produced for Camber Pharmaceuticals in Piscataway, New Jersey. The manufacturer is listed as Amora Pharma Pvt. Ltd in Sangareddy, Telangana, India. The Regulatory License Number is listed as 24/MDITS/2016F1G.*

This text provides information about Lurasidone Hydrochloride Tablets, including dosage instructions, storage recommendations, and contact details for further assistance. The tablets contain 40 mg of Lurasidone HCl, with dosing details available in the package insert. Storage at 20-25°C is advised, with excursions permitted up to 15-30°C. The medication is distributed by Camber Pharmaceutical in Piscataway, NJ, and a Medication Guide can be found at their website. Contact number for additional information is 1-866-495-1995.*

This is a description of Lurasidone Hydrochloride Tablets in 60 mg strength. Each tablet contains 60 mg of lurasidone HCl (equivalent to 55.87 mg of lurasidone). The dosage and usage instructions are provided in the package insert. The tablets should be stored at 20° to 25°C (68° to 77°F) with excursions allowed between 15° to 30°C (59° to 86°F). The manufacturer is Camber Pharmaceuticals located in Piscataway, New Jersey. For more information, contact the U.S. number provided: 1-866-495-1995.*

This is not-available.*

This text provides information about different drugs and their interactions. It mentions that Ketoconazole is a strong CYP3A4 inhibitor at a dose of 400 mg/day, Diltiazem is a moderate CYP3A4 inhibitor at a dose of 240 mg/day, and Rifampin is a strong CYP3A4 inducer at a dose of 600 mg/day. It also states that Lithium is prescribed at a dose of 600 mg BID. The text seems to refer to pharmacokinetics, specifically discussing fold change and 90% confidence interval relative to Lurasidone alone.*

This text provides information on the fold change and 90% confidence interval for PK parameters in cases of renal and hepatic impairment. It also includes details on how these parameters change in mild, moderate, and severe impairment. Furthermore, it mentions the population descriptions in terms of gender (females), race (Asian), and a comparison to Caucasians. This data can be useful in understanding the impact of impairment on pharmacokinetics and determining appropriate dosing adjustments.*